Yes, albuterol inhalers commonly cause jitteriness, tremor, and nervousness as documented side effects.
Albuterol-induced jitteriness and tremor are well-established, dose-related adverse effects that occur through β2-adrenergic receptor stimulation. According to FDA labeling, tremors occur in 20% of patients, nervousness in 4%, and these effects are considered probably or possibly drug-related 1. The mechanism involves direct action on skeletal muscle through β2-receptor stimulation, which shortens the active state of muscle contraction and has been correlated with hypokalaemia 2.
Clinical Significance and Patient Impact
Real-world data demonstrates these side effects are more common than clinical trials suggest:
- Patient-reported surveys show 58-60% of patients experience jitteriness and similar rates report tachycardia and restlessness 3
- Tremor is most common with nebulizer administration and oral formulations across all age groups 3
- In pediatric patients, distal tremor occurs in 80% of cases after standard nebulized doses 4
Dose-Response Relationship
The jitteriness is clearly dose-dependent 1, 2:
- Standard doses (2-4 puffs MDI): Tremor in 20% 1
- Higher doses (1-4 mg via dry powder): Progressive increase in tremor amplitude with each dose escalation 5
- Nebulized administration produces more frequent side effects than MDI 3
Important Clinical Context
These side effects typically resolve with continued use due to β2-receptor desensitization within the first few days of regular treatment 2. However, this tolerance development means:
- Tremor is most problematic with intermittent or as-needed use
- Patients on regular therapy often see resolution after initial doses
- The effect is not considered a major clinical problem for patients on maintenance therapy 2
Patient Behavior and Compliance Issues
The jitteriness has real consequences for medication adherence:
- 25-30% of patients reduce their bronchodilator dose on their own to avoid side effects 3
- 14-24% skip doses entirely due to unwanted effects 3
- Most patients report physicians advise them to "tolerate the side effects" rather than addressing the concern 3
Safety Considerations
While uncomfortable, the tremor and jitteriness are generally not dangerous:
- No clinically significant arrhythmias occur at standard doses 4
- QTc prolongation occurs but lacks clinical significance 4
- Potassium decreases (from 4.47 to 3.73 mEq/L) but remains clinically safe 4
- Fine motor skills testing shows increased tremor but no impairment in actual motor performance tasks 6
Practical Management
When patients report bothersome jitteriness:
- Switch from nebulizer to MDI with spacer - produces fewer systemic side effects 3
- Reduce dose if using higher than standard amounts
- Reassure that tolerance develops with regular use 2
- Consider levalbuterol (provides half the dose for equivalent efficacy) 7
- Ensure proper inhaler technique to maximize lung deposition and minimize systemic absorption
The side effect is real, common, and bothersome to patients, but it should not prevent appropriate bronchodilator use for acute symptoms or exacerbations.